Search
Menu
Home
HTB
2022
May
HTB
May 2022
Contents
Editorial
HTB May 2022 (2 May 2022)
Conference reports
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
CROI 2022: Other COVID-19 studies
Antiretrovirals
FDA approves dispersible dolutegravir/abacavir/3TC for children
Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits
Coinfections and complications
Asymptomatic COVID-19 is common in people living with HIV
Longest COVID-19 infection lasted 505 days in an immunocompromised person in London
Herd immunity unlikely to control COVID-19: opinion article from US NIAID
The challenges of prioritising access to molnupiravir and nirmatrelvir–ritonavir for COVID-19
Increased risk of blood clots after COVID-19: higher with underlying conditions and more severe symptoms
Two new platform vaccines against COVID-19 report phase 3 results
HIV prevention and transmission
A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton
Zimbabwe decriminalises HIV transmission
Cure-related research
Community webinar series on HIV cure-related cell and gene therapy
Other news
Family of Greek activist Zak Kostopoulos decry minimal sentence given to his killers
PDFs
HTB: no. 5 (2 May 2022) PDF downloads
HTB RSS
Early access
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024
i-Base guides updated online
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate